This technology is a panel of SNP (single nucleotype polymorphism) markers that are significantly more common in patients with major depression than in healthy patients. The variants are found in genes related to the cortisol stress response – corticotropin releasing hormone receptors (CRHR1 and 2) and the glucocorticoid receptor (GR). Genotyping with these markers could help identify patients at risk for depression, select patients for specific anti-depressant treatment, or determine inclusion criteria in clinical trials.Stage of Research
The inventors studied 40 patients with psychotic major depression, 26 patients with non-psychotic major depression and 29 healthy controls. They found GR and CRHR1 genotypes that contributed significantly to psychosis measures and CRHR1 contributed significantly to depression severity rating.